Lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia (BpALL) with chromosomal hyperdiploidy and with translocations affecting chromosome 12p11-13, accumulate high and low levels of methotrexate polyglutamates (MTXPGs), respectively. Recently a cryptic translocation, t(12;21) (p13;q22), has been demonstrated by molecular and fluorescence in situ hybridization techniques in this disease. The chimeric TEL-AML1 transcript, which has been associated with this translocation, can be detected in up to 25% of children with BpALL. We detected the TEL-AML1 and/or the AML1-TEL transcript in 30 (33%) of 91 patients studied. Levels of lymphoblast MTXPGs were lower in those with than in those without the TEL-AML1 translocation (P = 0.004). Hyperdiploidy was rare in lymphoblasts with the TEL-AML1 translocation (P = 0.047). Both ploidy (P = 0.0015) and TEL-AML1 status (P = 0.0043) were independently and significantly correlated with the log of the lymphoblast MTXPG level. However, the presence of TEL-AML1 or of hyperdiploidy accounted for only 22% of the variation of this value. Our results imply that each of 1.16 у DI and the presence of the TEL-AML1 translocation confers a 50% decrease in lymphoblast MTXPG level. When planning reduction of therapy for either of the two excellent outcome categories of hyperdiploid or TEL-AML1 BpALL, one should consider the difference between these two subgroups in the ability of lymphoblasts to accumulate MTXPGs. Leukemia (2001Leukemia ( ) 15, 1081Leukemia ( -1088 
Introduction
Characterization of prognostic features has facilitated the development of treatments tailored for specific subgroups of children with B-progenitor cell acute lymphoblastic leukemia (BpALL). 1, 2 In addition to age, sex and white cell count at diagnosis, certain cytogenetic abnormalities are of prognostic significance. The Philadelphia chromosome (t(9;22)(q34;q11)) confers an especially ominous outlook. 3, 4 In contrast, hyperdiploidy (DI Ͼ 1.16) carries an excellent prognosis. 5, 6 Among patients with hyperdiploidy, those with trisomies of both chromosomes 4 and 10 have the highest cure rate. 7 For the latter patients, the aim of future therapeutic modifications will be to reduce short-and long-term drug toxicities, while maintaining treatment efficacy. Knowledge of the contribution of different agents to the cure of such patients can be important in choosing how to reduce therapy. 8, 9 Large segment or cytogenetically evident translocations affecting chromosome 12p occur infrequently in childhood BpALL. 10 Recently, a cryptic translocation, t(12;21)(p13;q22), was detected by fluorescence in situ hybridization (FISH). [11] [12] [13] [14] Molecular studies revealed that this translocation joined together the helix-loop-helix region of the TEL gene located at chromosome 12p13 to almost the entire AML1 gene, located at chromosome 21q22. 15, 16 TEL gene rearrangements and the TEL-AML1 transcript have been demonstrated in up to 25% of children with BpALL. [17] [18] [19] Loss of the remaining normal TEL allele occurs in many of these patients. 13 , 20 The presence of TEL-AML1 appears to be associated with an excellent prognosis in children treated with either multidrug or with antimetabolite-based regimens. 17, [21] [22] [23] [24] Methotrexate (MTX) is an important component of all such treatments, both for central nervous system pre-symptomatic therapy and for continuation therapy. Given in high doses by infusion, followed by leucovorin rescue, it is the major component of the intensification phase of treatment in Pediatric Oncology Group (POG) therapeutic protocols. [6] [7] [8] [9] We and others have shown that lymphoblasts from children with BpALL metabolize MTX to its most active forms, longchain MTXPGs, more vigorously than blast cells from other leukemias. [25] [26] [27] [28] They form longer-chain MTXPGs, with five rather than three total glutamates and accumulate much higher levels of these long-chain MTXPGs. Accumulation of high levels of MTXPGs in lymphoblasts in vitro was associated with a higher cure rate 29 and in vivo with more rapid disappearance of leukemic blasts. 30 In particular, hyperdiploid lymphoblasts accumulate higher levels of long-chain MTXPGs than do non-hyperdiploid lymphoblasts. [31] [32] [33] These findings suggest that increased accumulation of MTX might explain in part the good prognosis of childhood BpALL in general and the excellent prognosis of those with hyperdiploid BpALL in particular.
Recently, analysis of a population of patients studied at diagnosis revealed that all 13 patients with translocations involving chromosome 12p failed to accumulate high levels of MTXPGs. 34 Despite this finding, none of these patients had failed therapy, suggesting that they had a good prognosis. We now report that lymphoblasts with the very specific t (12;21) that results in the TEL-AML1 fusion gene also fail to accumulate high levels of MTXPGs. Thirty of the TEL-AML1 study patients and 2702 of the POG patients had uninformative cytogenetics.
Methods
Between April 1989 and November 1994 the accumulation of MTXPGs in bone marrow lymphoblasts at diagnosis was successfully measured in vitro in a total of 138 children with BpALL, older than 1 year of age, who were enrolled on POG 8901. An initial study reported on 48 of these patients. 31 Two subsequent studies analyzed 95 of these patients 33, 34 who had had satisfactory cytogenetic analysis in addition to measurement of the lymphoblast MTXPG level. This group included 29 patients from the earlier study. 31 In the present study, bone marrow cell pellets were requested from virtually all (96%) of these 138 patients from the POG ALL Cell Bank at St Jude's Children's Research Hospital.
Frozen pellets were received from 100 (72%) of these patients and the presence or absence of the TEL-AML1 translocation determined in 91 (66%) of them. Within this group were 57 (60%) of the 95 patients reported previously including 23 (58%) of the 40 patients with Ͼ50 chromosomes. 33, 34 The TEL-AML1 status was determined for 30 (63%) of the 48 patients reported earlier. 31 Characteristics of these patients are tabulated in Table 1 and compared with those seen in 6786 POG patients with BpALL, less than 1 year old, who were used in the analysis of AlinC 14, 15 and 16 studies. Details of the techniques of incubation of lymphoblasts from these patients with 1.0 M 3 H-MTX for 24 h, of cell washing and of extraction and quantitation of MTX and MTXPGs by HPLC have been described previously. 31, 33 A lymphoblast MTXPG level Ͼ500 pmol/10 9 cells has been defined as high, based on biological advantage. 29, 30 BpALL was diagnosed by standard POG criteria. 35 Karyotype analysis was carried out in the POG Cytogenetics Reference Laboratory at the University of Alabama at Birmingham as well as in the Baylor Cancer Cytogenetics Laboratory, Houston, the Cytogenetics Laboratory, the University of Texas Southwestern Medical Center at Dallas and the Cytogenetics Laboratory, Medical College of Wisconsin, Milwaukee. The DNA index (DI) was determined at St Jude Children's Research Hospital in Memphis. 36 In this study, DI Ͼ 1.16 was used to assign hyperdiploidy rather than the number of chromosomes, because it was available on virtually every patient, whereas karyotyping of chromosomes was successful in only 61 (67%) of them.
Measurement of TEL-AML1 and AML1-TEL transcripts
RNA was harvested from cell pellets with a phenol-chloroform extraction using a commercial kit (trizol; Gibco, Burlington, Ontario, Canada), and was successfully obtained in 91 samples. 2.5 g of the RNA was subjected to reverse transcriptase polymerase chain reaction (RT-PCR), using random hexamers. The primers used to amplify the TEL-AML1 and the AML1-TEL transcripts as well as regions of the TEL and AML1 genes were previously published. 16, 17 PCR for TEL-AML1 and for AML1-TEL was performed for 40 cycles consisting of 94°C for 1 min, 58°C for 30 s and 72°C for 1 min. Sequencing of PCR products was by the dideoxy method, using a standard kit (Amersham, Oakville, Ontario, Canada), following the directions provided by the manufacturer.
The commonest breakpoint in the AML1 gene is in intron 1. However, the breakpoint is in intron 2 in a minority of patients, yielding a smaller TEL-AML1 transcript lacking the 39 bp exon 2 and a correspondingly larger AML1-TEL transcript. 37 The larger and smaller fragments due to these alternate breakpoints are shown in Figure 1 .
For TEL-AML1 detection, the 509 (or 470) bp product was digested with the restriction endonuclease Ava1 to yield unique 356 and 153 (or 114) bp fragments. For the AML1-TEL product, the Hha1 restriction endonuclease cut the 343 (or 382) bp product into identifying 262 and 81 (or 120) bp fragments.
The amplified TEL-AML1 and AML1-TEL fragments are shown in Figure 1 . Initially, PCR yielded a smaller product, a 254 (215) bp fragment, rather than the expected 509 (470) bp fragment. The missing region comprised nt 97 to nt 350 inclusive of the AML1 sequence. PCR of the same region of the AML1 gene revealed the smaller species as well. This region is GC rich and therefore prone to folding and incomplete amplification. Addition of 6% dimethylsulfoxide overcame this phenomenon and yielded the correct length DNA fragment. Small amounts of this product are present in Figure 1 . 
Statistical considerations
The primary focus of this analysis was to compare the presence and absence of the TEL-AML1 translocation with lymphoblast MTXPG levels and with ploidy, using the Wilcoxon test 38 and exact conditional chi-square, 38 respectively. To quantitate the potential association between MTXPG levels and the presence or absence of the TEL-AML1 translocation, a Hodges-Lehmann 38 confidence interval for scale was used. The association of lymphoblast MTXPG levels and subclassification of the TEL-AML1 by transcript presence was conducted by the Spearman correlation, 38 using negative vs small vs large Tel-AML1 and AML1-TEL as ordinal variables. In order to study the joint relationship of lymphoblast MTXPG level with both ploidy and TEL-AML1, a multiple regression Leukemia analysis 39 was conducted, using the natural logarithm of MTXPG as the dependent variable. This transformation seemed to equalize the variation in the four defined groups. All statistical tests were two-sided.
Results
The presence of the TEL-AML1 and the AML1-TEL transcript was determined successfully in 91 (66%) of 138 children with BpALL studied on POG 8901. Characteristics of these patients are summarized in Table 1 and compared with those in 6786 POG patients with BpALL (see Methods). The distribution of these patients seems similar to BpALL patients in general. The white cell count is somewhat higher in the test patients which is normal for cell bank studies, since such patients typically provide more material for study.
The distribution of total MTXPG levels in children with and without the TEL-AML1 translocation is shown in Figure 2 and Table 2 . Twenty-two (79%) of the 28 children with the TEL-AML1 translocation and who were not hyperdiploid had a 'clinically significant' lower MTXPG level (Ͻ500 pmol/10 9 cells), while six had MTXPG levels previously associated with improved outcome (Ͼ500 pmol/10 9 cells). By the Wilcoxon test, MTXPG levels in TEL-AML1 lymphoblasts were significantly lower than in lymphoblasts without the TEL-AML1 translocation (P = 0.004). While there was considerable overlap between these two groups, the median MTXPG level of those without TEL-AML1, 654 pmol/10 9 cells, was close to the 90th percentile of MTXPG levels of those with TEL-AML1, 686 pmol/10 9 cells (Table 2 ). Point estimate is that the median MTXPG level is 2.1-fold higher without than with the TEL- AML1 translocation. We are 95% confident that it is between 1.4-and 3.3-fold higher. There were 17 children whose lymphoblasts were hyperdiploid with a DI Ͼ 1.16 of which 15 lacked the TEL-AML1 translocation. TEL-AML1 was present in 28 of the 74 patients with a DI р 1.16 ( Figure 2 ). Evaluation by exact conditional chi-square demonstrated that hyperdiploidy is rare in patients with the TEL-AML1 translocation (P = 0.047). Lymphoblast MTXPG levels were significantly lower in those with than without the TEL-AML1 translocation in the 74 nonhyperdiploid patients, P = 0.008 (two-sided Wilcoxon test).
Thirteen patients had the TEL-AML1 transcript, four children had the AML1-TEL transcript and 13 children had both. In 24 patients, the translocation was located within the first intron giving a larger (509 bp) TEL-AML1 fragment and/or a smaller (343 bp) AML1-TEL fragment. In six patients, the translocation was within the second intron, yielding a smaller (470) TEL-AML1 fragment and a larger (382 bp) AML1-TEL fragment. Spearman correlations for lymphoblast MTXPG levels vs the presence or absence as well as the site of translocation of these transcripts yielded R = −0.05, P = 0.78 for TEL-AML1 and R = 0.08, P = 0.67 for AML1-TEL. These results are inconclusive, perhaps reflecting too few patients. They do not infer no correlation.
The relation of the log of the lymphoblast MTXPG level was compared to the presence and absence of the TEL-AML1 translocation and to the presence (DI Ͼ 1.16) and absence (DI р 1. The final model predicting MTXPG levels from this analysis is shown in Table 3 . The model is valid in the sense that the full (saturated model) was fit to the data (ie 4 means were modeled via four parameters initially). The interaction term was dropped for lack of predictive value. For patients lacking Table 3 Model fitted values of lymphoblast MTXPG levels in children with BpALL by the presence and absence of the TEL-AML1 translocation and by ploidy for the final model (no interaction). This is the antilog of the means of the log scales with 95% confidence limits ( both the TEL-AML1 translocation and hyperdiploidy, the mean predicted lymphoblast MTXPG level is 496 pmoles/10 9 cells. Each of 1.16 у DI and the presence of the TEL-AML1 translocation appears to confer a 50% decrease in lymphoblast MTXPG level.
Cell pellets were available for nine of the 14 patients previously reported to have a translocation involving 12p, determined cytogenetically. 34 Seven of these nine patients had the TEL-AML1 translocation in addition to a translocation involving 12p (present in patients 2, 4, 5, 6, 10, 11, 13; absent in patients 8,14, Table 1, Ref 34 ). In addition, two of the three patients reported to have del(12p) had the TEL-AML1 translocation (present in patients 16, 17, absent in patient 15). 34 Patient 17 had del(12p) in the modal clone and a 12p translocation in the minor clone. Thus, eight of the 10 patients with a 12p translocation studied previously had a TEL-AML1 translocation identified as well. We determined the TEL-AML1 status of 24 (62%) of the 39 non-hyperdiploid patients who did not have a 12p11-13 translocation reported previously. 34 Six (25%) had a TEL-AML1 translocation. These results suggest a close association between the occurrence of the TEL-AML1 translocation and of other translocations involving chromosome 12p.
Discussion
The addition of intensification therapy, following induction, has been associated with improved EFS in children with BpALL. 8, 9 A major component of such enhanced therapy has been infusion of MTX at high doses every few weeks. 8, 9 We reported previously that the extent of accumulation of MTXPGs in lymphoblasts of children with BpALL treated in the early 1980s correlated with EFS. 29 In a confirmatory study, levels of MTXPGs accumulated in lymphoblasts in vivo were found to correlate with the rapidity of decline of circulating blasts following MTX treatment. 30 We and others showed that hyperdiploid BpALL lymphoblasts accumulated high levels of MTXPGs. [31] [32] [33] Such levels may account in part for the good response these patients have to MTX-intensive treatment regimens. These results provide direct clinical evidence that the ability of lymphoblasts to metabolize the pro-drug MTX to its active forms, MTXPGs, is important to the outcome of treatment.
Recently, we found that BpALL lymphoblasts, which had translocations affecting chromosome 12p11-13, accumulated low levels of MTXPGs. 34 Such lymphoblasts rarely showed hyperdiploidy. Toward completion of this study, we learned of the occurrence of the t(12;21)(p13;q22), a cryptic translo-cation seldom recognized cytogenetically, but demonstrated by FISH and by RT-PCR. This translocation is the most common cytogenetic abnormality yet detected in BpALL and is associated with an excellent prognosis in most studies. Since this TEL-AML1 translocation involves chromosome 12p, we were interested to determine whether lymphoblasts with this specific translocation also lacked the ability to accumulate MTXPGs effectively.
Results presented here demonstrate that the observation of low lymphoblast MTXPG levels associated with 12p translocations extends to the commonest of these, namely the TEL-AML1 translocation. Indeed, we found that levels of lymphoblast MTXPGs were significantly lower in those with than in those without TEL-AML1. This difference was evident despite considerable overlap in MTXPG levels ( Figure 2) .
Analysis revealed that hyperdiploidy is rare in lymphoblasts with the TEL-AML1 translocation as it was for other 12p translocations 34 and as has been reported by others. 17 Both DI Ͼ 1.16 and the presence of the TEL-AML1 translocation proved to be highly significantly correlated with the log of the lymphoblast MTXPG level in childhood BpALL.
The results imply that each of 1.16 у DI and the presence of the TEL-AML1 translocation confers a 50% decrease in lymphoblast MTXPG level. Thus roughly a four-fold difference exists between these two good prognosis subgroups of BpALL in their ability to metabolize MTX and to accumulate MTXPGs (Table 3 ). It will be important to consider this difference in MTX metabolism in planning reductions in therapy for groups of these patients whose cure rate is highly favorable.
It is interesting to speculate whether it is patients with the TEL-AML1 translocation who have benefited most from the increased reliance of treatment on high-dose infusions of MTX during intensification. Such treatments might compensate for the reduced ability of TEL-AML1 lymphoblasts to accumulate high levels of MTXPGs. Knowledge of the therapeutic outcome of patients with TEL-AML1 treated prior to the introduction of such therapy might provide an answer to this question. At the same time, it is important to remember that success of treatment reflects use of many effective agents. Perhaps TEL-AML1 lymphoblasts are particularly sensitive to another component of therapy, such as L-asparaginase, and MTX cytotoxicity plays a lesser role in their cure. Another possibility is that patients with the TEL-AML1 translocation have blasts that are more sensitive to low levels of MTXPGs.
Some reports suggest that the presence of the AML1-TEL transcript was sought only in those patients found to have the TEL-AML1 transcript. 17 We analyzed each sample for both and found four patients expressing only the AML1-TEL message. This may account in part for the 30% incidence of the TEL-AML1 translocation in this series of patients, which is higher than the 25% usually reported. Neither the presence nor the size of one or other of these chimeric messages showed a correlation with lymphoblast MTXPG levels, but patient numbers were insufficient to draw any conclusions.
We found the TEL-AML1 translocation as a second cytogenetic abnormality in eight of 10 patients studied previously who had a 12p translocation. 34 While we linked cytogenetically identified 12p translocations to low lymphoblast MTXPG levels in this initial study, current results raise the possibility that it may be the TEL-AML1 translocation, rather than that of the macroscopically identified segment of 12p, which is implicated in this association.
LOH for the normal TEL allele has been found to be very common in patients with the TEL-AML1 translocation. 13, 20 It
Leukemia is tempting to speculate that disruption of both TEL alleles may be associated with low MTXPG levels in this population. Alternately, it may be that disruption of the AML1 rather than the TEL gene is linked to low lymphoblast MTXPG levels. Certainly, accumulation of MTXPG in blasts from patients with ANLL is much lower than in BpALL blasts. 28 Several genes are involved in the regulation of accumulation of MTXPGs. The reduced folate carrier (RFC1) transports folate and MTX into cells. 40 Levels of RFC1 message are increased in hyperdiploid lymphoblasts. 41, 42 MTXPGs are synthesized from MTX by the enzyme folate polyglutamate synthetase (FPGS) 43 and are hydrolysed to MTX by gammaglutamyl hydrolase (GGH). 44 Differences in expression of these genes have been linked to extent and lineage specificity of MTXPG synthesis in childhood ALL. 45, 46 Studies are in progress to link levels of expression of the RFC1, FPGS and GGH genes in BpALL lymphoblasts with levels of accumulation of MTXPGs and with the presence of TEL-AML1 or of hyperdiploidy. 
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